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The association between heavy consumption of
analgesics and nephropathy was first described in
Canada in 1961 [1]. Thirty-seven such patients were
reported in 1968 [2, 3], and an additional 314 were
reported in 1972 from a survey of Canadian nephrol-
ogists [41, which provides a baseline from which an
evaluation of the effect of removal of phenacetin can
be made.
The analgesic taken by the great majority of these
Canadian patients was a 222® tablet, containing
phenacetin, 160 mg; acetylsalicylic acid, 220 mg;
caffeine, 32 mg; and codeine, 8 mg. Phenacetin was
available in this and other analgesic combinations
over the counter, but sales were largely limited to
pharmacies. In 1970, the phenacetin was voluntarily
replaced by Frosst Company in this and their related
compound analgesics by an additional 220 mg of
acetylsalicylic acid. In 1973, federal legislation was
passed prohibiting the sale of phenacetin in combina-
tion with salicylic acid and its derivatives. As the sale
of phenacetin had been almost completely in combi-
nation with acetylsalicylic acid, this virtually elimi-
nated phenacetin both from prescription and over-
the-counter markets. Estimated Canadian consump-
tion of phenacetin and acetylsalicylic acid (ASA) is
shown in Figure 1. Up to 8 mg of codeine can be sold
in combination with other analgesics without pre-
scription in Canada and may commonly contribute to
habituation and occasionally to addiction [31. Anti-
pyrine (phenazone) has not recently been sold in
Canada.
Some points of interest in relation to analgesic
nephropathy contributed by Canadian authors
include: formulation of the concept of the syndrome
of APC analgesic abuse [3]; the finding that the
upper gastrointestinal complications of heavy con-
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sumption of APC analgesics are far more common
than nephropathy [51; the first major study in man of
kidney tissue in early stages of this disorder by elec-
tron microscopy suggesting that an increase in med-
ullary collagen is a very early feature and providing
further evidence that the primary lesion occurs in the
medulla [6]; and the demonstration of a major papilla
to cortex gradient in rabbits and dogs for '4C-ASA
and metabolites in hydropoenia [7].
Syndrome
The syndrome associated with abuse of APC anal-
gesics containing ASA, phenacetin, and caffeine
(APC) [31 is of considerable help in pointing to the
diagnosis of analgesic nephropathy which is often
missed [81. Analgesic consumption is frequently
denied, and the syndrome can often be recognized
without prior knowledge of analgesic consumption
[91.
Patients with this syndrome are usually females
between the ages of 30 and 65 yr, with a history of
heavy APC consumption for 5 to 20 yr before renal
disease is discovered. Clinical features of renal dis-
ease are frequently preceded by long-standing evi-
dence of psychiatric disorder and headache, and the
more recent onset of upper gastrointestinal disease
and anemia. Renal symptomatology may include
flank or abdominal pain, acute or chronic pyelone-
phritis, bacteriuria, pyuria (often without infection),
hematuria, hypertension, acidosis, passage of papil-
lae, and renal failure.
The psychiatric component in most of the patients
must be considered primary in the genesis of analge-
sic abuse and also with respect to treatment. Patients
may present with psychiatric problems, including
anxiety and depression. Poor adjustment in marriage
and work is common, as is abuse or overdose of
other drugs and habituation to alcohol. Most give a
history of long-standing emotional instability and
personality disorder, chiefly of an immature and
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Fig. 1. Estimated Canadian consumption as indicated by two-year means for acetylsalicylic
acid [21, 221 and phenacetin used by the pharmaceutical industry [23, 241. Canadian popula-
tion increased from 12.3 million in 1946 to 22.4 million in 1974 [25, 261. The closed circles
and solid line (.s) represents phenacetin x 10; the open circles and broken line (00)
represent acetytsalicylic acid x l0.
dependent nature. In the Canadian series of 351
patients [4], 36% were considered to have major
and 40% moderately severe psychiatric problems.
The majority of patients who abuse analgesics
state the primary reason for consumption is head-
ache. Migraine is often mentioned, but the symptoms
are frequently not characteristic. More often, a feel-
ing of tension, heaviness, or fullness in the head is
described. Some patients may later take increasing
quantities of analgesics for reasons unrelated to
headaches—for relief of tension, to get a "lift" or
other psychic benefit. Less frequently, back pain,
arthritis, abdominal pain, inability to concentrate,
fatigue, or desire to increase work output are reasons
stated for consumption.
Gastrointestinal symptoms often precede sympto-
matic evidence of renal disease by several years.
Peptic ulceration, with a higher than usual frequency
of gastric involvement is common and is probably
due to salicylate. Ulcers in these patients are fre-
quently resistant to treatment and have a high inci-
dence of bleeding, often leading to surgery such as
gastrectomy. Of the 351 Canadian patients [4], 50%
had had radiologic evidence of peptic ulcer and 36%
had undergone an upper gastrointestinal tract
operation.
Anemia, out of proportion to the degree of renal
failure, is a common feature, and hemoglobin values
of <10 gIdl were present at the time of diagnosis of
nephropathy in 42% of the Canadian patients [4].
Blood loss from chronic ASA consumption and from
peptic ulceration, with iron deficiency, is an impor-
tant component, and ASA may also cause anemia
unrelated to bleeding. Absorptive defects may be
present in those who have had a gastrectomy and in
whom macrocytic anemia has been observed. Phena-
cetin may result in hemolytic anemia, usually of the
oxidative type, with a hyperplastic marrow, reticulo-
cytosis, Heinz bodies, distorted red blood cell mor-
phology, and met- and sulfhemoglobinemia with
cyanosis; these features are no longer seen in Canada
since the removal of phenacetin from the market.
Minor features also reported with heavy APC con-
sumption include dementia [10] and darkening of the
urine on standing related to phenacetin [11].
Management
A good long term outlook is more likely when the
patient admits the true quantity of compound analge-
sics taken, accepts that habituation is a factor, and
that the habit has been injurious. ASA blood levels
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and information from family or pharmacist may be
helpful. The assistance of a psychiatrist may be
invaluable, particularly when depression is promi-
nent. Establishment of the reason why the patient
started taking analgesics and the factors that led to
abuse permits the most appropriate treatment.
A trial in hospital off the offending analgesics,
particularly those containing caffeine, is important
for those with headaches, as these sometimes are
predominantly of the caffeine withdrawal type and
may then largely disappear. Only occasionally have
our patients discarded all analgesics permanently.
When this is not possible, we introduce a trial with
propoxyphene, adding oral codeine when necessary
under strict control. If abuse is related to relief of
anxiety, diazepam or a comparable drug may be
given. Effective treatment of hypertension and uri-
nary tract infection can be critical in arresting the
decline in renal function, and long-term therapy with
an antibacteriaI agent may be required. Some
patients require therapy for acidosis, electrolyte dis-
turbances, and other manifestations of renal failure.
A normal salt and fluid intake is ordinarily advised.
Patients are followed initially at monthly intervals
when blood samples are drawn for ASA levels, ser-
um creatinine, and hemoglobin; and urine is obtained
for routine analysis and culture when indicated. Sali-
cylate consumption can immediately be checked by
testing urine with Phenistix® or ferric chloride. If
abuse of any other drug is suspected, this is estab-
lished by assay. Blood pressure is measured, special
events and consumption of analgesics and other
drugs since the last visit are reviewed, and the pre-
vious month's ASA level is discussed. The approach
is primarily supportive.
Early relief of ureteral obstruction due to sloughed
papillae is critical, especially if infection is present;
and occasionally, multiple pieces of necrotic papillae
lodge in the pelvis leading to repeated episodes of
obstruction and may require removal surgically. Spe-
cial care must be taken to avoid volume or sodium
depletion, as acute renal failure can supervene, espe-
cially if major surgery is undertaken under these
circumstances.
Most of these patients are acceptable for manage-
ment by dialysis or transplantation when necessary.
Rarely, renal function improves enough that dialysis
can later be withdrawn [121.
Urothelial neoplasms, particularly of the renal pel-
vis, may complicate analgesic nephropathy, at times
several years after consumption of phenacetin has
ceased [13]. The appearance of hematuria should
particularly make one suspect this possibility. Urine
cytology at regular intervals may be of value.
Outcome
At the end of 1971, a survey of Canadian nephrolo-
gists was undertaken by one of the authors for the
Canadian Society of Nephrology, and data concern-
ing 351 cases of analgesic nephropathy were
obtained. About 60 new cases were reported annual-
ly for the three years 1969—1971. The prevalence was
50 per million in Toronto, where reporting was prob-
ably most complete. Renal function declined in 42%
of the 222 patients with follow-up values for serum
creatinine, particularly in those who continued use of
analgesics, or had severe impairment at the time of
diagnosis. Twenty-five percent showed improvement
in function, particularly those who stopped taking
analgesics. Followup was mainly for one to three
years. Two other studies [10, 11] illustrate that when
nephropathy is established, continued consumption
of APC analgesics usually leads to a continuing
decline in renal function, and that abstinence fre-
quently leads to stabilization or improvement. ASA,
caffeine, and codeine may be less likely to cause a
progressive decline in renal function than APC and
codeine (Fig. 2).
Results of a new survey (1972—1976) represent, to
date, about one half the population covered by the
first [41. The new data are all from specific nephrolo-
gists and hospitals who contributed to the first sur-
vey and come mainly from London, Hamilton,
Kingston, Toronto, Ontario; St. John, New Bruns-
wick; Victoria, British Columbia; and two hospitals
in Montreal, Quebec.
The number of new cases presenting each year has
fallen an average by about 40% for the last three
years (1974—1976), compared with 1970—1973. The
number reaching end-stage, as reflected by the num-
bers commencing dialysis, however, has not greatly
changed (Table 1). This may be interpreted as evi-
dence that ASA can contribute to deterioration of
function in established analgesic nephropathy. It is
important, however, to appreciate that 87% of the
114 new cases had a history of heavy phenacetin
ingestion for three years or more and 50% for ten
years or more; only 5% claimed they had taken no
phenacetin.
A comparison of changes in renal function for the
two surveys is shown in Table 2. The first survey
represents a period when analgesic consumption was
primarily the combination of ASA, phenacetin, caf-
feine, and codeine; and the second survey, consump-
tion of combined ASA, caffeine, and codeine. The
results show a slight improvement for the second
survey.
In 1976, 2.5% of patients on dialysis in Canada had
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Analgesic consumption ceased
Patients
New
patients
starting
dialysis
1970 23 6
1971 35 5
1972 31 10
1973 31 5
1974 17 6
1975 14 8
1976 21 5
analgesic nephropathy (SHIMIzu A: Canadian
dialysis and transplant registry statistics, 1976, per-
sonal communication). This compares with 5% for
Ontario in 1972 [14].
Discussion
Removal of phenacetin voluntarily by pharma-
ceutical companies or decreased consumption relat-
ed to legislation has been reported to lead to a
decrease in new cases of analgesic nephropathy [15],
Analgesic consumption continued
— APC&C
ACC
to a decline in mortality due to this disorder [16], and
to a decrease in the frequency of papillary necrosis
found at autopsy [17]. The effects of reduced con-
sumption appear particularly after four to six years
[15, 16]. Our recent survey was made six years after
a major decrease in availability and three years after
virtual elimination of phenacetin. Prospective
recording of the incidence of analgesic nephropathy
for several more years will be required to determine
the long term effects of the removal of phenacetin in
Canada.
There is relatively little information about the
course of patients with analgesic nephropathy who
continue to use or abuse analgesics containing ASA.
Reports from Australia [18, 191 have suggested that
ASA, even in small doses, and other analgesics or
antiinflammatory agents may lead to progression of
the renal disease with further papillary necrosis.
Nanra [20] has reported 47 patients who presented
with analgesic nephropathy within the previous 2/2
years, and had been taking acetylsalicylic acid, sali-
cylamide and caffeine as Vincent's® powders, from
which phenacetin had been removed in 1968. Renal
function may continue to deteriorate in many
patients with established analgesic nephropathy who
continue to take analgesics containing ASA, although
perhaps less rapidly than in those who continue to
take analgesics containing phenacetin.
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Fig. 2. Changes in creatinine clearance over one to eight years after analgesic nephropathy
was diagnosed in patients who stopped taking analgesics containing phenacetin or ace jylsalicylic
acid (ASA) (left), compared with those who continued to take either ASA-caffeine-codeine
(ACC) or ASA-phenacetin-caffeine-codeine (APC & C) analgesics (right). Renal function
deteriorated in only one of the patients who continued to ingest the ACC preparation, but it
deteriorated in most of the patients who continued to ingest the APC & C preparation. (Re-
produced with permission from Can Med Assoc J [11].)
Table 1. Incidence of new cases of analgesic nephropathy and
patients starting dialysis in hospitals reporting continuously 1970—
1976a
a Data was selected from individual nephrologists and hospitals
from 1971 and 1976 surveys to include only those with continuous
reporting from 1970 to 1976. Legislation virtually removed phena-
cetin from Canadian markets in 1973.
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Table 2. Comparison of initial and follow-up renal function: 1971 and 1976 surveys
No. of cases Followup renal functiona % cases
Worse' Improved" Unchangedb
Initial renal function 1971 1976 1971 1976 1971 1976 1971 1976
Normal
Mild to moderate impairment
Severe impairmente
All cases
30
124
68
222
19
75
28
122
33
35
57
42"
5
35
39
31d
0 5
24 25
37 54
25 29
67
41
6
34
90
40
7
40
a 64% of patients had renal function followed by serum creatinine determination for three or more years and 88% for one or more years in
the 1976 survey, compared with 45% and 82% for the 1971 survey. All patients had followup data for at least three months.
For serum creatinine values <4 mg/dl, renal function was considered unchanged unless the serum creatinine had changed by 0.5 mg/dl.
When the value was >4 mg/dl the change required was 20%.
Serum creatinine >5 mgldl.
d 50% of these patients in the 1971 survey developed terminal renal failure requiring dialysis, compared with 60% in the 1976 survey.
Patients with analgesic nephropathy will continue
to present, and our index of suspicion must remain
high. The importance of this disorder rests on the
fact that it is a potentially preventable cause of renal
disease and renal failure.
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